Scholarlink

<p>Despite compelling evidence that tumor-derived extracellular vesicles (TEVs) exhibit either pro- or antitumorigenic phenotypes, pharmacological efforts have focused primarily on their indiscriminate suppression. Here, we propose a strategy of “switching TEVs off and on” to redirect them toward an immunogenic phenotype. Designed as a nanoproteolysis-targeting chimera (Nano-PROTAC) for TEV reprogramming, EVOTAC is composed of tripartite building blocks that integrate a PROTAC and a photosensitizer via a cancer biomarker-responsive cleavable linker and spontaneously self-assemble into supramolecular nanostructures. Upon biomarker-guided activation preferentially in tumors over normal tissues, EVOTAC initially eliminates TEVs by selectively degrading intracellular proteins involved in extracellular vesicle (EV) biogenesis. Subsequent localized laser irradiation reactivates EV generation, prompting tumor cells to predominantly produce immunogenic TEVs in response to photodynamic therapy (PDT). TEVs generated through this switching-off-and-on strategy independently exert pleiotropic effects by inhibiting tumor growth, migration, and metastasis while increasing mature dendritic cells and cytotoxic T lymphocytes in lymphoid organs and tumor tissues. This TEV-toggling process, therefore, significantly enhances both innate and adaptive immune responses to photoimmunotherapy, which leads to a complete regression of triple-negative breast cancer (TNBC) and prevents metastasis and recurrence. Our study highlights the potential of this therapeutic approach for precise TEV modulation and encourages further exploration, adding new breadth to the growing list of EV-targeting cancer immunotherapy concepts.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Switching tumor-derived extracellular vesicles off and on via targeted proteolysis to shift toward immunogenic phenotypes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月9日

查看全文
  • Yeongji Jang,
  • Byeongmin Park,
  • Jiwoong Choi,
  • Do Young Jin,
  • Eun Hye Kim,
  • Hochung Jang,
  • Jae-Hyeon Lee,
  • Eunbyeol Ko,
  • Dongwon Shin,
  • Kyungsu Kim,
  • Woohyeong Lee,
  • Ansoo Lee,
  • Myung Chul Lee,
  • In-Cheol Sun,
  • Hong Yeol Yoon,
  • Sangmin Lee,
  • Sun Hwa Kim,
  • Jooho Park,
  • Kwangmeyung Kim,
  • Jun-Seob Kim,
  • Yoosoo Yang,
  • Man Kyu Shim

摘要

Despite compelling evidence that tumor-derived extracellular vesicles (TEVs) exhibit either pro- or antitumorigenic phenotypes, pharmacological efforts have focused primarily on their indiscriminate suppression. Here, we propose a strategy of “switching TEVs off and on” to redirect them toward an immunogenic phenotype. Designed as a nanoproteolysis-targeting chimera (Nano-PROTAC) for TEV reprogramming, EVOTAC is composed of tripartite building blocks that integrate a PROTAC and a photosensitizer via a cancer biomarker-responsive cleavable linker and spontaneously self-assemble into supramolecular nanostructures. Upon biomarker-guided activation preferentially in tumors over normal tissues, EVOTAC initially eliminates TEVs by selectively degrading intracellular proteins involved in extracellular vesicle (EV) biogenesis. Subsequent localized laser irradiation reactivates EV generation, prompting tumor cells to predominantly produce immunogenic TEVs in response to photodynamic therapy (PDT). TEVs generated through this switching-off-and-on strategy independently exert pleiotropic effects by inhibiting tumor growth, migration, and metastasis while increasing mature dendritic cells and cytotoxic T lymphocytes in lymphoid organs and tumor tissues. This TEV-toggling process, therefore, significantly enhances both innate and adaptive immune responses to photoimmunotherapy, which leads to a complete regression of triple-negative breast cancer (TNBC) and prevents metastasis and recurrence. Our study highlights the potential of this therapeutic approach for precise TEV modulation and encourages further exploration, adding new breadth to the growing list of EV-targeting cancer immunotherapy concepts.